MicroRNA-155 (miR-155) is frequently upregulated in various types of human cancer; however, its role in cancer angiogenesis remains unknown. Here, we demonstrate the role of miR-155 in angiogenesis through targeting von Hippel-Lindau (VHL) tumour suppressor in breast cancer. Ectopic expression of miR-155 induced whereas knockdown of miR-155 inhibited human umbilical vein endothelial cell network formation, proliferation, invasion and migration. Furthermore, mammary fat pad xenotransplantation of ectopically expressed miR-155 resulted in extensive angiogenesis, proliferation, tumour necrosis and recruitment of proinflammatory cells such as tumour-associated macrophages. Expression of VHL abrogated these miR-155 effects. Moreover, miR-155 expression inversely correlates with VHL expression level and is associated with late-stage, lymph node metastasis and poor prognosis, as well as triple-negative tumour in breast cancer. These findings indicate that miR-155 has a pivotal role in tumour angiogenesis by downregulation of VHL, and provide a basis for miR-155-expressing tumours to embody an aggressive malignant phenotype, and therefore miR-155 is an important therapeutic target in breast cancer.
INTRODUCTION
Angiogenesis has a major role in tumour growth, progression and metastasis. Initially, angiogenic activity is absent in early neoplasms. However, as tumours progress, oxygen becomes depleted within the core which creates hypoxic conditions that induce HIFafamily proteins through degradation of the von Hippel-Lindau (VHL) tumour suppressor and production of angiogenic factors, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), platelet-derived growth factor, epidermal growth factor, placental growth factor and angiopoietins-1. [1] [2] [3] [4] [5] [6] Tumour production of these factors promotes recruitment of endothelial precursor cells from the bone marrow, and vascular permeability factors such as VEGF allow these cells to penetrate vessel walls and migrate from a vessel in close proximity to the tumour towards the core of the tumour where these angiogenic stimuli are produced. Cells attach to pre-existing vessels and one another during proliferation to form tubular sprouts in pushing the circulatory network deeper into the tumour. 2, [7] [8] [9] The delivery of blood supply, via newly generated blood vessels, into the centre of the tumour allows for continued tumour growth. 10, 11 MiRNAs are processed short single-stranded RNA that forms a ribonucleoprotein complex with Argonaute proteins to inhibit gene expression. 12 Although a number of miRNAs are deregulated in human cancer, only a few miRNAs have been reported to regulate tumour angiogenesis. For example, miR-107 and miR-591 suppress tumour angiogenesis, tumour growth and the expression of VEGF by inhibition of HIF1b and HIF1a, respectively. 13, 14 MiR-93-expressing U87 glioma cells induce tumour blood vessel formation and tumour growth by integrin-b8. 15 Accumulating studies show frequent upregulation of miR-155 in various human malignancies, including breast, lung, pancreatic and colon cancers, as well as B-cell lymphoma and chronic lymphocytic leukaemia. [16] [17] [18] [19] [20] We and others previously demonstrated that miR-155 regulates a number of cell processes including cell survival, growth, migration, invasion, epithelial-tomesenchymal transition and immune response, [21] [22] [23] [24] [25] [26] [27] [28] [29] yet the role of miR-155 in tumour angiogenesis remains elusive. In the current study, we provide in vitro and in vivo evidence that miR-155 promotes breast cancer angiogenesis by targeting VHL and that the upregulation of miR-155 is associated with metastasis, poor prognosis and triple-negative tumour in breast cancer.
RESULTS

miR-155 promotes angiogenesis
We initially observed that VEGF induced miR-155 expression ( Figure 1a) . To investigate the role of miR-155 in angiogenesis, we ectopically expressed and knocked down miR-155 in human umbilical vein endothelial cells (HUVECs) in the absence and presence of VEGF, respectively (Figures 1b and c) . HUVECexpressing miR-155 increased network formation, as measured by branch points and total tube lengths (top panels of Figure 1d ). In agreement with previous finding, 30, 31 VEGF treatment induced in vitro angiogenesis; however, knockdown of miR-155 decreased VEGF-induced network formation (bottom panels of Figure 1d ). As angiogenesis requires endothelial cell proliferation, migration and invasion, 32, 33 we investigated the effect of miR-155 on these aspects by performing 5-bromo-2-deoxyuridine (BrdU) incorporation, and Boyden Chamber assays with (invasion) and without (migration) Matrigel, respectively. Ectopic miR-155 expression increased, whereas knockdown of miR-155 decreased BrdU incorporation compared with control ( Figure 1e) . Similarly, ectopic expression of miR-155 increased, whereas its inhibition decreased invasion and migration of HUVEC (Figures 1f and g ).
To analyse the effect of miR-155 on breast cancer angiogenesis in vivo, we infected BT474 cells, which express low level of endogenous miR-155, with lentiviral pMIRNA-155 (BT474/miR-155) and empty vector as control (BT474/ctrl) (Figure 2a) . It was noted that the level of miR-155 in BT474/miR-155 cells was comparable Figure 1 . Expression of miR-155 induces and knockdown of miR-155 represses in vitro angiogenesis. (a, b) HUVECs were transfected with indicated oligos and then cultured in the absence or presence of VEGF for 48 h. (c) HUVECs were treated with VEGF for indicated times and then subjected to qRT-PCR analysis of miR-155 level. The HUVECs were examined for (d) endothelial network formation (scale bar, 250 mm) and branch points and total tube length quantification, (e) proliferation (scale bar, 250 mm) by BrdU incorporation, (f ) invasion ( Â 100 magnification) and (g) migration ( Â 100 magnification). Images representative of experiments was performed in triplicates for two times. (Mean±s.e.m., n ¼ 6). *Po0.05. Figure S1) . Stable BT474/miR-155 and BT474/ctrl cells were xenotransplanted into the right and left mammary fat pad of nude mice, respectively. The tumours from BT474/miR-155 and the control cells were monitored by IVIS Imaging system on day 5 (top of Figure 2b ) and week 6 (bottom of Figure 2b ) of the transplantation. Figure 2c shows BT474/miR-155 tumours grew at faster rate compared with BT474/ctrl. The average BT474/miR-155 tumour weight was approximately two times heavier than controls (Figure 2d ). Blood vessels were apparent on the surface of BT474/miR-155 tumours, whereas control tumours had smaller and less defined blood vessels ( Figure 2e ). We next examined the expression of a panel of angiogenic factors in these tumours. Immunoblot analysis revealed that HIF1a, HIF2a and VEGF levels were elevated in BT474/miR-155 tumours compared with controls ( Figure 2f ). In addition, a significant increase in neoangiogenic blood vessels and proliferation, as well as mitotic index, was observed in BT474/miR-155 tumour when compared with BT474/ctrl (Figures  2g and h; Supplementary Figure S2) . Furthermore, immunofluorescence staining with antibodies against F4/80 and CD31 revealed macrophage infiltration in BT474/miR-155 tumours that was largely undetectable in control tumours (Figure 2i) . Expression of miR-155 in these tumours was confirmed by quantitative real-time PCR (qRT-PCR; Figure 2f ). Taken collectively, these data indicate miR-155 has a pivotal role in tumour angiogenesis.
MiR-155 down-regulates VHL and is associated with clinical features With the observation of miR-155 inducing in vitro and in vivo angiogenesis, we next determined the underlying mechanism.
As increase of VEGF, HIF1a and HIF2a protein levels was observed in BT474/miR-155 tumours (Figure 2f ), we initially examined the mRNA levels of VEGF, HIF1a and HIF2a in miR-155-transfected BT474 cell and its xenograft tumour. Real-time PCR analysis showed that HIF1a and HIF2a mRNA levels did not change while VEGF was considerably elevated in BT474/miR-155 tumours (Supplementary Figure S3) . Because VHL is an E3 ligase of HIF1a and HIF2a, 34 we next assessed whether miR-155 regulates VHL level. Western blot analysis revealed that ectopic expression of miR-155 in BT474 and HUVEC cells reduced VHL protein expression but not its mRNA level (Figure 3a) . Accordingly, the expression of HIF1a, HIF2a and VEGF was increased in miR-155-transfected cells (Supplementary Figure S4) . Furthermore, knockdown of miR-155 in HS578T and MDA-MB-157 cells, in which endogenous miR-155 is high, increased VHL expression (Figure 3b ). Expression of VHL was also decreased in BT474/ miR-155 xenograft tumours compared with BT474/vector controls ( Figure 3c ; Supplementary Figure S5 ). In addition, inverse Figure 3f ). These data suggest miR-155 downregulation of VHL in vitro and in vivo.
Furthermore, we examined whether miR-155 levels are related to clinical feature of breast cancer. Table 1 shows that elevated miR-155 is significantly associated with late-stage (stage III/IV) and high-grade tumours, lymph node metastasis and triple-negative breast cancer. Kaplan-Meier analysis of all 231 patients demonstrated a statistically significant negative correlation between overall survival (OS) and miR-155 expression level (Po0.001; Figure 4a ). To extend this observation, we separated the patients into two groups by stage (for example, late stages (III/IV) and early stages (I/II)) and asked whether within each subgroup miR-155 expression predicts patient survival. In both groups, high miR-155 expression was still a prognostic factor (Figures 4b and c ). In addition, the patients whose tumours express high levels of miR-155/low levels of VHL exhibit even worse prognosis (Figure 4d vs Figure 4b ). These findings suggest that miR-155 regulates VHL resulting in a more aggressive phenotype in breast cancer.
Further univariate analysis revealed that several factors, including stage, histology and miR-155 expression were associated with poor clinical outcome (Po0.05; Table 2 ). Of them miR-155 expression was a relative strong predictor of poor OS with a hazard ratio of 2.408 (95% CI, 1.491-3.888, Po0.001). A multivariate Cox proportional hazards model with following variables: age, stage, grade, histology and miR-155 expression, was used to analyse their simultaneous association with OS. Although tumour stage was a strong independent predictor of outcome (P ¼ 0.003), miR-155 expression appeared to be even better independent predictor (Po0.001). These results indicate that miR-155 is a prognostic marker in breast cancer.
Identification of VHL as a direct target of miR-155 To determine whether miR-155 directly regulates VHL, we initially searched pre-compiled databases but did not identify any canonical miR-155 binding sites within VHL-3'UTR region. We next performed AGO2 RNA immunoprecipitation in attempt to identify direct interaction between miR-155/AGO/RISC complex with mRNA of VHL (Figure 5a ). Co-transfection of pre-miR-155 or pre-miR-control with Myc-AGO2 followed by anti-Myc immunoprecipitation and RNA isolation yielded RNA, where qRT-PCR showed VHL mRNA enrichment in miR-155/AGO/RISC complex compared with control/AGO/RISC complex (Figure 5b) . However, the same isolated RNA revealed no significant enrichment in HIF2a or VEGF mRNAs in miR-155/AGO/RISC compared with control/AGO/RISC complex (Figure 5b ). These findings suggest direct interaction between VHL mRNA and miR-155/AGO/RISC complex that prompted us to carry out further sequence analysis. Using RNA22 database, we found an atypical motif in VHL-3'UTR that partially matches the miR-155 'seed' sequence ( Figure 5c ).
To determine whether this motif is responsible for the downregulation of VHL by miR-155, we cloned the VHL-3'UTR (that is, 66-bp containing putative miR-155 response element (MRE)) into the pMIR-REPORT luciferase vector (VHL-WT 3'UTR). In parallel, a mutated seed site in VHL-3 0 UTR was also cloned into the pMIR-REPORT vector (VHL-MUT 3 0 UTR). Transfection of VHL-WT 3 0 UTR into a panel of breast cancer cell lines showed the luciferase levels inversely correlated with endogenous miR-155 expression (Figure 5d ). Co-transfection of miR-155 and VHL-WT 3 0 UTR into BT474 resulted in B30% decrease in luciferase activity, whereas no significant change was detected in the VHL-MUT 3 0 UTR transfection (Figure 5e ). Further, inhibition of miR-155 in HS578T, a cell line with high endogenous miR-155, and co-transfection with VHL-WT 3 0 UTR resulted in almost 60% increased luciferase activity whereas no change was observed in the cells transfected with VHL-MUT 3 0 UTR (Figure 5f ). As miR-155 targeting sequence is located at very end of VHL-3 0 UTR, we also created two pMIR-REPORT constructs, one of which was 0.8-kb VHL-3 0 UTR containing MRE and the other was a truncated deletion of miR-155-MRE sequence (VHL-3'UTR-0.68, Supplementary Figure S7A ). Luciferase assays revealed that miR-155 repressed the activity of pMIR-REPORT-VHL-3'UTR-0.8 but not pMIREPORT-VHL-3 0 UTR-0.68 (Supplementary Figure S7B) . These data indicate that the VHL is a direct target gene of miR-155.
Expression of VHL rescues miR-155-induced angiogenesis in vitro and in vivo
Having demonstrated miR-155 induces in vitro and in vivo angiogenesis and inhibits VHL expression, we proceeded to determine whether miR-155 promotes angiogenesis through downregulation of VHL. We introduced HA-tagged VHL cDNA expression vector without the 3 0 UTR, which can escape miR-155 regulation, together with pre-miR-155 into HUVEC (Figure 6a) . Notably, expression of VHL largely abrogated the effects of miR-155 on HUVEC endothelial network formation, BrdU incorporation, invasion and migration (Figures 6b-e) .
We further evaluated the effect of ectopic expression of VHL on miR-155-induced angiogenesis in orthotopic breast cancer model. Lentiviral pMIRNA-155 stably infected BT474 BT474 cells ( Figure 2a) were transfected with pcDNA-HA-VHL or pcDNA (Figure 7a ). After injection of the cells into mammary fat pat of nude mice, the animals were examined for tumour growth for 6 weeks. As shown in Figures 7b and c , miR-155-induced tumour growth and tumour weight were significantly suppressed by VHL reintroduction. Furthermore, VHL restoration inhibited blood vessels, tumour-associated macrophage (TAM) infiltration and proliferation induced by miR-155 (Figures 7d-f) . These results indicate that miR-155 promotes breast cancer growth and angiogenesis primarily by targeting VHL. Abbreviations: CI, confidence ratio; HR, hazard ratio.
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VHL (Figures 2, 5-7)
. Our findings show that VHL is downregulated by miR-155 through direct interaction with a site within the 3 0 UTR of VHL. Although the VHL gene is frequently inactivated or silenced in clear cell renal carcinomas, haemangioblastomas, and pheochromocytomas through germline and/or somatic mutations or promoter hypermethylation, loss of VHL in breast cancer is not attributed to these anomalies. 37, 38 Our findings suggest that VHL loss in breast cancer can be partly attributed to miR-155 overexpression.
A well-characterized function of VHL is targeting of the HIFafamily members (HIF1, 2, and 3a) for proteolytic degradation, thus preventing dimerization with their respective b-subunits in forming the functional transcriptional factor. Evidence suggests that HIF2a is the main downstream VHL target to have a causal role in VHL -/-renal carcinogenesis. 34 Under normoxic conditions where oxygen is present, members of the prolyl hydroxylase family (PHDs) enzymatically hydroxylates prolyl residues within the HIFa subunit to form high affinity binding sites for VHL. VHL, an E3 ubiquitin ligase, promotes rapid degradation of HIFa subunit. Conversely, as oxygen depletes during hypoxia, PHDs do not hydroxylate HIFa subunits, which then stabilize and dimerize with the HIFb subunit in forming the functional transcriptional factor. In this report, we observed miR-155 downregulates VHL expression, resulting in HIF2a and HIF1a stability both in vitro and in vivo (Figures 2f and 3c) . Accumulating studies have demonstrated that HIF1a and HIF2a promoted tumour angiogenesis, tumour invasion and triple-negative breast cancer phenotype by regulating a number of target genes including IL6, VEGFA, CD44, and PKM2 etc. 39, 40 Notably, a recent report showed that inhibition of HIF1a and HIF2a by SHARP1 repressed triple-negative breast cancer aggressiveness. 41 These findings suggest that miR-155 regulates VHL/HIF pathway to induce tumour angiogenesis and metastasis. This notion is further supported by the data that transfection of VHL cDNA without 3 0 UTR rescued miR-155-induced angiogenesis (Figures 6 and 7) . We also noted a consequential increase in VEGF (Figures 2f and 3c) , which likely contributes to the observed increase angiogenic activity both in HUVECs and breast cancer xenografts.
In addition, VHL also exhibits HIF-independent functions that include regulation of apoptosis and cell senescence. VHL also has a role in microtubule stabilization, maintenance of the primary cilium, regulation of extracellular matrix formation and cell-to-cell adhesion. 42 Although we have identified the proangiogenic activity of miR-155 through downregulation of VHL, whether MicroRNA-155 promotes breast cancer angiogenesis W Kong et al miR-155 subverts these VHL-mediated physiological processes for promoting malignancy remains to be investigated.
An angiogenic tumour is associated with microenvironments and immune cells that facilitate tumour progression and malignancy. [43] [44] [45] The endothelium of tumour blood vessels provides a physical structure for circulating immune cells derived from the bone marrow to adhere, whereas angiogenic stimuli promotes chemotaxis, migration and infiltration of these cells into the tumour. They include macrophages, neutrophils, mast cells and myeloid-derived suppressor cells. [7] [8] [9] 46 In agreement with this, we observed infiltration of TAMs in miR-155 tumours that was largely absent in control tumours (Figures 2i  and 7f) . In future studies, cytokine analysis could provide further insights on the role of miR-155 in tumour inflammation, leading to tumour progression. For instance, tumour production of IL-4 activates TAMs, which in turn produce matrix-degrading enzymes to promote tumour invasion. TAMs can also produce proangiogenic and miR-155 inducing factors, such as VEGF, IL-1, bFGF and TNFa, to initiate a vicious feed forward cycle between tumour angiogenesis and inflammation 24, 27, 31, 47, 48 (Figure 8 ). In agreement with miR-155 induction of angiogenesis, we also show that upregulation of miR-155 is associated with metastasis, late-stage/high-grade tumour and poor prognosis in breast cancer. Moreover, its prognosis value is independent of tumour stage (Figure 4 ). In addition, we found elevated level of miR-155 in a significant portion of triple-negative breast cancer (Table 1) . A recent study demonstrated that upregulation of miR-155 in BRCA1-deficient or BRCA1-mutant human breast tumours and that BRCA1 epigenetically represses miR-155 expression by recruiting HDAC2 complex to the miR-155 promoter. 49 Previous reports showed that downregulation/mutation of BRCA1/2 is associated with triple-negative breast cancer. 50, 51 While the role of miR-155 in triple-negative breast cancer is current unknown, these findings suggest that miR-155 could be a valuable marker and target of this subgroup tumour.
Our findings are important for several reasons. We show miR-155 directly downregulates VHL, which provides another mechanism for VHL loss in breast cancer in addition to mutations and promoter hypermethylation. We also present for the first time, the role of miR-155 in tumour angiogenesis that contributed to increased progression of breast tumours. Moreover, miR-155 could be an independent prognostic marker of breast cancer and has a role in triple-negative tumour. Taken together with our earlier reports that link miR-155 with breast cancer chemoresistance and mammary epithelial-to-mesenchymal transition, invasion and migration, 22, 23 miR-155 is a critical therapeutic target in breast cancer.
MATERIALS AND METHODS
Reagents and antibodies
TRIZOL, Pre-miR miRNA and Taqman Pri-miRNA kit were purchased from Life Technologies Corporation (Carlsbad, CA, USA). 5-Bromo-2 0 -deoxyuridine Labelling and Detection Kit I was purchased from Roche Applied Sciences (Indianapolis, IN, USA). Anti-VHL rabbit polyclonal antibody was 
MiRNA qRT-PCR detection and quantification
Hsa-miR-155 and U6 microRNA levels were detected using TaqMan microRNA Reverse Transcription kit (Applied Biosystem, Foster City, CA, USA). Briefly, 200 ng of total RNA from each cell line and tumour RNA were used for primer specific reverse transcriptase (RT) in both hsa-miR-155 and U6, and then 2 ml of the RT product was used for subsequent qPCR. The qPCR was performed on ABI HT9600 (ABI, Foster City, CA, USA) and data were collected and analysed using ABI SDS version 2.3. To calculate relative concentration, miR-155 and U6 C T values for all samples were obtained. A normalized expression for each sample was obtained by dividing C T of miR-155 by the same sample's U6 CT and designated as DC T . This value is then transformed by performing 2^-(DC T ). Furthermore, the (DDC T ) method was used in comparing miR-155 expression in immortalized cells to cancer cells or normal breast to cancer tissues according to ABI's protocol.
Plasmids and oligos
Lenti-pMIRNA1-155, pMIRNA1 vector and packaging kit were purchased from System Biosciences (Mountain View, CA, USA). Anti-sense 2 0 -Omethyl-RNA control and 2 0 -O-methyl-miR-155 (miR-155-ASO) were custom synthesized from Integrated DNA Technologies (Coralville, IA, USA). pMIR-REPORT was purchased from Life Technologies Corporation. Wild type and mutant predicted MRE within VHL-3 0 UTR was subcloned to pMIRREPORTin SpeI/HindIII sites. The following oligos were used: wild type, F-ctagTTTTTTTTTTTTTTTTTTTTTTTAAAGCTGTTTTTTAATACATTAAATGGTGC TGAGTAAAGGAAA and R-agctTTTCCTTTACTCAGCACCATTTAATGTAT TAAAAAACAGCTTTAAAAAAAAAAAAAAAAAAAAAAA; mutant, F-ctagTTTTT TTTTTTTTTTTTTTTTTTAAAGCTGTTTTTTAATAGTAATTATGGTGCTGAGTAAAG GAAA and R-agctTTTCCTTTACTCAGCACCATAATTACTATTAAAAAACAGCTT TAAAAAAAAAAAAAAAAAAAAAAA. In addition, 0.8-kb VHL-3 0 UTR containing putative miR-155-MRE and its deletion mutant (for example, lacking miR-155-MRE sequence) were amplified by PCR and the PCR products were cloned to pMIR-REPORT in SpeI/HindIII sites. Primers are: F-TCGACTAGTA CAGTGGCTCATGCCTGTAATCCC for both constructs, R1-CCGAAGCTTT ATTTCCTTTACTCAGCACCAT and R2-CCGAAGCTTGAACTTCACCGTCTCTTA AGAG CG for the deletion mutant. Myc-tagged Argonaute 2 construct was generously provided by Dr Gregory J Hannon (Cold Spring Harbor Laboratory). HA-VHL was from Dr Michael Ohh (University of Toronto).
Cell culture and tumour specimens
Human breast cancer cell lines were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and cultured at 37 1C in 5% CO 2 . Primary HUVEC were obtained from American Type Culture Collection (Manassas, VA, USA) and maintained in Vascular Cell Basal Medium in the presence and absence of VEGF, epidermal growth factor, FGF, IGF-1, L-glutamine, heparin sulphate, hydrocortisone, ascorbic acid and 2% fetal bovine serum, and cultured at 37 1C in 5% CO 2 . Primary human breast cancers and normal breast specimens were obtained from patients who underwent surgery at H. Lee Moffitt Cancer Center and approved by the institutional review board and in accord with an assurance filed with and approved by the US Department of Health and Human Services. Each cancer specimen contained at least 80% tumour cells, as confirmed by microscopic examination. Tissues were preserved by snap-freeze and stored at À 80 1C for subsequent protein and RNA extraction with TRIZOL reagent for RT-qPCR analysis as per instructions.
Endothelial tube formation assay HUVEC was transfected with pre-miR-155, miR-155-ASO and control oligos for 12 h and then seeded onto Matrigel-coated 96-well plates. Pre-miR-155-and control-transfected cells were cultured in a medium without VEGF; whereas miR-155-ASO-and control-transfected cells were cultured in a medium containing VEGF. After 24 h incubation, network formation was captured using Zeiss inverted light microscope in combination with AxioVision Software (Carl Zeiss Micoscopy, LLC, Thornwood, NY, USA).
Quantification of networks was done by measuring total tube length and counting branch points per defined area using ImageJ image data analysis software.
Invasion and migration assay HUVEC was transfected with pre-miR-155, miR-155-ASO and control oligos for 12 h and then seeded in upper chamber of Boyden Chambers coated with or without Matrigel in the absence (pre-miR-155-transfected cells) or presence (miR-155-ASO-treated cells). All lower chambers contained normal HUVEC culture medium. After incubation for 48 h, invasion and migration were examined under a Nikon inverted light microscope.
AGO2 RNA co-immunoprecipitation BT474 cells were transfected with myc-AGO2, pre-miR-155 or control precursor oligos followed by anti-myc/AGO2 RNA immunoprecipitation as previously described. 52, 53 Complementary strand DNA synthesis was done using ImProm-II Reverse Transcription System from Promega (Madison, WI, USA). qRT-PCR was performed using EXPRESS SYBRGreenERqPCR Supermix with Premixed ROX from Life Technologies Corporation. Primers to detect VHL mRNA: F-ctgcccgtatggctcaactt and R-gtgtgtccctgca;tctctgaag; HIF2a mRNA: F-ttgatgtggaaacggatgaa and R-ggaacctgctcttgctgttc and VEGF mRNA: F-gcacccatggcagaagg and R-ctcgattggatggcagtagct.
Target in vitro luciferase report and BrdU incorporation assays Luciferase report assay was performed as described previously. 22, 23 For BrdU incorporation experiment, HUVEC was transfected with pre-miR-155, miR-155-ASO and control oligos. Following incubation for 36 h, cells were processed for BrdU incorporation according to the manufacture's protocol and images captured using Zeiss inverted light microscope and AxioVision Software.
Xenotransplantation and analysis of neoangiogenic blood vessels, proliferation and mitotic index Experimental procedures involving animals were reviewed and approved by the Institutional Animal Care and Use committee. Animal care was in accord with institution guidelines. Fifty thousand cells from BT474 which were transfected with various plasmids indicated in the figure legends were injected into mammary fat pad of 6-week-old female nude mice (Charles River, Wilmington, MA, USA). Tumour growth was monitored every 3 days by imaging and caliper measurements (L Â W Â D), until the largest tumour surpassed 1400 mm 3 in size. Tumours were extracted and processed for western, qRT-PCR, immunohistochemistry, immunofluorescence and histopathological analysis. Neoangiogenic blood vessels and proliferation were evaluated by immunostaining of tumour sections with anti-CD31 and Ki-67. Mitotic indices were determined on haematoxylin and eosin-stained sections under microscopy.
Statistical analysis
Statistical comparisons were based upon unpaired Student's t-test. Tumour-related death was calculated and follow-up time was determined from the date of diagnosis to the date of tumour-related death or the last follow-up for survivors, and OS was estimated with the Kaplan-Meier method. Patients dying from causes other than their cancer were censored at their date of death. The regression analyses were adjusted for tumour stage (I/II and III/IV). These analyses were performed using the SPSS 11.5 Statistical Software (SPSS, IBM, Chicago, IL, USA). Hazard ratios were assessed using the univariate and multivariate Cox proportional hazards models. Clinical variables, including age, stage, grade and tumour histology, were adjusted in multivariate Cox proportional hazards model. Pp0.05 was considered to be statistically significant.
